ombitasvir/paritaprevir/ritonavir and dasabuvir

DRUG8 trials

Sponsors

AbbVie

Conditions

Chronic Hepatitis CChronic Hepatitis C InfectionCirrhosisHepatitis C VirusHepatitis C Virus (HCV)

Phase 2

A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients

CompletedNCT01782495

AbbVieChronic Hepatitis C Infection

Start: 2013-02-25End: 2017-07-13Updated: 2017-11-07

A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection

CompletedNCT02356562

AbbVieChronic Hepatitis C Infection

Start: 2015-02-03End: 2017-07-07Updated: 2017-12-20

Phase 3

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection

CompletedNCT02442284

AbbVieChronic Hepatitis C, Cirrhosis, Hepatitis C Virus

Start: 2015-05-13End: 2016-10-31Updated: 2017-10-16

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil

CompletedNCT02442271

AbbVieChronic Hepatitis C Infection

Start: 2015-04-27End: 2016-09-26Updated: 2017-08-01

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease

CompletedNCT02487199

AbbVieHepatitis C Virus (HCV)

Start: 2015-09-30End: 2016-12-05Updated: 2017-12-04

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma

TerminatedNCT02504099

AbbVieChronic Hepatitis C Infection

Start: 2015-07-31End: 2016-12-31Updated: 2017-12-12

ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection

CompletedNCT02517515

AbbVieHepatitis C Virus (HCV)

Start: 2015-07-31End: 2017-06-30Updated: 2017-10-27

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection

CompletedNCT02609659

AbbVieHepatitis C Virus (HCV)

Start: 2015-10-28End: 2016-12-28Updated: 2019-12-10

Related Papers

Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients.

2019-02-012 citations

Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials.

2018-10-056 citations

Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir

Antimicrobial Agents and Chemotherapy2015-11-2420 citations

An Interferon-free Antiviral Regimen for HCV after Liver Transplantation

New England Journal of Medicine2014-11-11402 citations